Abiopharma

🔍 ORVILLE JACOB A (Executive)

Company: EXACT SCIENCES CORP (EXAS)

Report Date: 2026-03-23

Detailed Transactions and Holdings:

• Acquired 53,323 shares of Common Stock (Direct)
  Date: 2026-03-23 | Code: A | equity_swap_involved: false | shares_owned_after: 153,726.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 153,726 shares of Common Stock (Direct)
  Date: 2026-03-23 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F3
• Sold 1,774 shares of Common Stock (Direct)
  Date: 2026-03-23 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F3
• Sold 6,581 shares of Stock Options (Right to Buy) at $98.18 per share (Derivative)
  Date: 2026-03-23 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F5, F4, F4
• Sold 38,707 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-23 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F6, F8, F7, F7

Footnotes:

• F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent.
• F2: At the effective time of the Merger (the "Effective Time"), each performance based restricted stock unit ("PSU") outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration") in respect of each share of the Issuer's common stock, par value $0.01 per share ("Common Stock") subject to such PSU, less any applicable tax withholding.
• F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
• F4: These options became exercisable on February 14, 2024.
• F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
• F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.
• F7: These RSUs vest in four equal annual installments beginning on February 25, 2027.
• F8: At the Effective Time, each RSU granted under an Issuer stock plan outstanding as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time.